Teleflex has filed a patent for devices, systems, and methods to alter the position or force relationship of tissues or anatomical structures. The invention can be used to improve patency or fluid flow through a body lumen or cavity, such as reducing constriction of the urethra caused by an enlarged prostate gland. The patent includes a claim for a method to treat benign prostatic hyperplasia by inserting an interventional device through the urethra, injecting a therapeutic agent into the prostate gland, and using an endoscopic device to view the position of the interventional device. GlobalData’s report on Teleflex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teleflex, Non-invasive physiological monitoring was a key innovation area identified from patents. Teleflex's grant share as of September 2023 was 61%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating benign prostatic hyperplasia using interventional device
A recently filed patent (Publication Number: US20230293166A1) describes a method for treating benign prostatic hyperplasia (BPH). The method involves inserting an interventional device through the urethra of a subject until it reaches the prostatic urethra. The interventional device consists of a tubular elongate device coupled with a hollow needle that has a sharp distal tip. The needle is then advanced into a lateral lobe of the prostate gland, and a therapeutic agent is injected into the lobe to decrease its size. The position of the interventional device is monitored using an endoscopic device.
The therapeutic agent used in the method can cause the lateral lobe to decrease in size by forming a coagulative lesion that is subsequently resorbed. This therapeutic agent may involve the use of heat energy, specifically radiofrequency energy. Alternatively, the therapeutic agent can be a substance that dissolves, degrades, cuts, breaks, weakens, softens, modifies, or remodels the lateral lobe.
The method also includes various additional steps and features. The interventional device can be inserted through the urethra either to a position within the urethra distal to the prostate gland or into the urinary bladder. The distal portion of the needle can be repositioned, and more of the therapeutic agent can be injected into the lateral lobe if needed. Lidocaine can be introduced to the urethra to provide anesthesia. The endoscopic device used for monitoring can be a cytoscope. The interventional device may have side ports for introducing or removing fluids. The needle and the introducing sheath of the tubular elongate device can be made of various materials, including stainless steel, nickel-titanium alloy, titanium, or combinations thereof. The position of the interventional device can be detected using radiopaque markers, such as distal and proximal marker bands. It is important to confirm that the distal marker band is positioned within the lateral lobe before injecting the therapeutic agent.
Overall, this patent describes a method for treating BPH that involves the targeted injection of a therapeutic agent into the lateral lobe of the prostate gland. The method offers potential benefits for patients suffering from BPH and may provide an alternative to existing treatment options.
To know more about GlobalData’s detailed insights on Teleflex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
